Vera Therapeutics
VERA
172 hedge funds and large institutions have $1.51B invested in Vera Therapeutics in 2025 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 71 increasing their positions, 48 reducing their positions, and 40 closing their positions.
232% more call options, than puts
Call options by funds: $38.9M | Put options by funds: $11.7M
48% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 48
1.31% more ownership
Funds ownership: 98.88% → 100.19% (+1.3%)
2% less capital invested
Capital invested by funds: $1.53B → $1.51B (-$24.5M)
4% less funds holding
Funds holding: 179 → 172 (-7)
15% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 40
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$51.7M |
| 2 |
Morgan Stanley
New York
|
+$40.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$36.1M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$27M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$23.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
-$52.8M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$40.2M |
| 3 |
CC
Commodore Capital
New York
|
-$39.6M |
| 4 |
SC
Samlyn Capital
New York
|
-$23.5M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$18.9M |
VERA Hedge Fund Activity: Q2 2025 in Review
172 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q2 2025, worth a combined $1.51B — down 1.6% from $1.53B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of VERA and 34 opened new positions — a net loss of 6 holders — while 48 trimmed existing stakes and 71 added.
The largest buyer was Deerfield Management, adding an estimated $51.7M. The largest seller was Holocene Advisors, exiting entirely with an estimated $52.8M sold.
- 172 institutional investors held Vera Therapeutics (VERA) as of Q2 2025, down from 179 in Q1 2025.
- Funds reported $1.51B of Vera Therapeutics stock for Q2 2025, down 1.6% quarter-over-quarter.
- 34 funds opened new Vera Therapeutics positions in Q2 2025 and 40 closed out, a net change of -6 holders.
- The largest Vera Therapeutics buyer in Q2 2025 was Deerfield Management, an estimated $51.7M added.
- The largest Vera Therapeutics seller in Q2 2025 was Holocene Advisors, an estimated $52.8M sold.
Based on aggregated 13F filings for Q2 2025.